ADC Therapeutics SA reports results for the quarter ended in March - Earnings Summary

ADC Therapeutics SA

09/05/2022 14:30

* ADC Therapeutics SA  ADCT.N  reported a quarterly adjusted
loss
of 22 cents​​ per share for the quarter ended in March. The mean
expectation of seven analysts for the quarter was for a loss
of 70 cents per share.
    * Revenue was $46.50 million​;  analysts expected $28.94
million. 
    * ADC Therapeutics SA's reported EPS for the quarter was a
loss
of 22 cents​.
    * The mean earnings estimate of analysts had risen by
about 9.9%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * ADC Therapeutics SA shares had fallen by 25.5% this
quarter and
lost 45.8% so far this year.
    * The company reported a quarterly loss of $16.66 million.
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $34.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 9 at 01:29 p.m.  ​All
figures in US dollars unless otherwise stated